NCT00817375Unknown不适用
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks
研究概览
简要总结
The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.
详细描述
The purpose of this study is
- to determine whether genomic effects on antidepressant response differed by class of drug,
- whether genomic differences between drug responders and nonresponders predict the response of antidepressant and
- to construct the prediction model for antidepressant treatment in order to aid to select the their genetically matching drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
- •interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
排除标准
- •received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
- •potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
研究组 & 干预措施
SSRI treated group
Experimental
SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
干预措施: SSRI treated group (Drug)
non-SSRI treated group
Active Comparator
non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
干预措施: non-SSRI treated group (Drug)
结局指标
主要结局
Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks
时间窗: 6 weeks
次要结局
- Biological value at 0 and 6 weeks(6weeks)
研究者
Doh Kwan Kim
M.D., pHD
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Pharmacogenomics Studies of AntidepressantsAntidepressive AgentsPharmacogeneticsVenlafaxineFluoxetineMajor Depressive DisorderNCT01204086National Cheng-Kung University Hospital200
Unknown
不适用
Predict Antidepressant Responsiveness Using PharmacogenomicsDepressive SymptomsDepressionNCT01228357Samsung Medical Center1,000
Unknown
不适用
Development of Pharmacogenomic Method to Predict Antidepressant ResponsivenessAntidepressant Drug Adverse ReactionDepressionNCT00817011Samsung Medical Center1,000
Unknown
不适用
Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic PhenotypeDepressionNCT01352559Samsung Medical Center1,000
撤回
不适用
Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision SupportDepressionNCT03952494Weill Medical College of Cornell University